Go Pro
NASDAQ:DBVT

DBV Technologies Q3 2024 Earnings Report

DBV Technologies logo
$12.35 -0.16 (-1.28%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$12.35 0.00 (0.00%)
As of 09/18/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DBV Technologies EPS Results

Actual EPS
-$0.80
Consensus EPS
-$1.90
Beat/Miss
Beat by +$1.10
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$1.07 million
Expected Revenue
$1.17 million
Beat/Miss
Missed by -$100.00 thousand
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

DBV Technologies' Q3 2026 earnings is estimated for Wednesday, October 28, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

DBV Technologies Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More DBV Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email.

About DBV Technologies

DBV Technologies (NASDAQ:DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children. The company has also evaluated its epicutaneous immunotherapy platform in other allergy programs, including milk allergy. Viaskin Peanut has undergone clinical development and regulatory review in the United States, although it has not become an approved commercial treatment.

Founded in France, DBV Technologies operates internationally and has historically focused its development and regulatory activities on the United States and Europe. The company is headquartered in the Paris area and its American depositary shares trade on the Nasdaq under the symbol DBVT. Its leadership and corporate structure have changed over time as the company has advanced its clinical programs and worked with regulators.

View DBV Technologies Profile